Patents by Inventor Claire L. SUTHERLAND
Claire L. SUTHERLAND has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115612Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: ApplicationFiled: November 15, 2023Publication date: April 11, 2024Applicant: Juno Therapeutics, Inc.Inventors: Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST, Mark J. GILBERT, He LI
-
Patent number: 11944647Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: GrantFiled: June 22, 2022Date of Patent: April 2, 2024Assignee: Juno Therapeutics, Inc.Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
-
Publication number: 20240018268Abstract: Provided herein are anti-idiotype antibodies that specifically recognize anti-CD19 antibody moieties, in particular, anti-CD19 antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of anti-idiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-CD19 CART cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.Type: ApplicationFiled: July 29, 2017Publication date: January 18, 2024Applicant: Juno Therapeutics, Inc.Inventors: Collin HAUSKINS, Mark D. HEIPEL, Claire L. SUTHERLAND, Taher SATHALIYA, Jeff SMITH
-
Publication number: 20230149458Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: ApplicationFiled: June 22, 2022Publication date: May 18, 2023Applicant: Juno Therapeutics, Inc.Inventors: Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST, Mark J. GILBERT, He LI
-
Patent number: 11413310Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: GrantFiled: June 1, 2018Date of Patent: August 16, 2022Assignee: Juno Therapeutics, Inc.Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
-
Publication number: 20210198372Abstract: Provided are methods of treatment, such as methods involving administering and/or determining dosing of, cell therapy, such as of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range and/or window for dosing, for example, based on the estimated probabilities of risk of developing a toxicity and estimated probabilities of a treatment outcome or response, such as treatment, reduction nor amelioration of a sign or symptom thereof, or degree or durability thereof, following administration of the cell therapy or engineered cells. In some aspects, the methods involve administering an agent capable of modulating the engineered cells. Also provided are methods of ameliorating and/or treating a toxicity.Type: ApplicationFiled: November 30, 2018Publication date: July 1, 2021Applicant: Juno Therapeutics, Inc.Inventors: Tina ALBERTSON, Jacob Randolph GARCIA, Mark J. GILBERT, Jens HASSKARL, Mark D. HEIPEL, He LI, Claire L. SUTHERLAND, Nikolaus Sebastian TREDE
-
Publication number: 20210128616Abstract: Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.Type: ApplicationFiled: December 7, 2018Publication date: May 6, 2021Applicant: Juno Therapeutics, Inc.Inventors: Kedar Himanshu DAVE, Todd DEVRIES, Ronald James HAUSE, Jr., Ryan P. LARSON, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Nathan K. YEE, Rachel K. YOST
-
Publication number: 20210071258Abstract: Provided herein are methods for determining if a subject is at risk for developing a toxicity, e.g., neurotoxicity, following administration of a therapy, such as an immunotherapy or cell therapy, e.g., a chimeric antigen receptor (CAR) T cell therapy based on the expression, in a sample obtained from the subject, of one or more genes or gene products that are associated with and/or correlate to a risk of developing toxicity following administration of the therapy. In some aspects, the sample is a sample obtained from the subject prior to receiving the therapy. Also provided are methods for treating a subject having a disease or condition, such as acute lymphoblastic leukemia (ALL), according to a particular treatment regimen, in some cases involving administration of the immunotherapy or cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.Type: ApplicationFiled: August 31, 2018Publication date: March 11, 2021Applicant: Juno Therapeutics, Inc.Inventors: Robert F. DUBOSE, Nels Eric OLSON, Seamus RAGAN, Claire L. SUTHERLAND
-
Publication number: 20200147136Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: ApplicationFiled: June 1, 2018Publication date: May 14, 2020Applicant: Juno Therapeutics, Inc.Inventors: Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST
-
Publication number: 20200078400Abstract: Provided are methods of determining dosing of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range for dosing by the estimated probabilities of risk of developing a toxicity and estimated probabilities of response to the engineered cells when administered.Type: ApplicationFiled: December 1, 2017Publication date: March 12, 2020Applicant: Juno Therapeutics, Inc.Inventors: He LI, Tina ALBERTSON, Mark D. HEIPEL, Claire L. SUTHERLAND